Spinraza (Nusinersen)

Spinraza (Nusinersen)

Spinraza

Nusinersen

12 mg/5 mL (2.4 mg/mL) in a single-dose vial

Ionis Pharmaceuticals, Inc.

Medical Use

Spinraza is an antisense oligonucleotide targeting the survival motor neuron-2 (SMN2) gene, used to treat spinal muscular atrophy (SMA) in both children and adults.

Recommended Dosage:

  • Initial Treatment: Administer 12 mg (5 mL) of Spinraza intrathecally. Begin with 4 loading doses: the first three doses should be given every 14 days, and the fourth dose should be administered 30 days after the third.
  • Maintenance Treatment: Following the loading doses, continue with a maintenance dose of 12 mg every 4 months.

Spinraza should be administered by healthcare professionals skilled in performing lumbar punctures.